Patients with AST or alkaline phosphatase > ULN are eligible for inclusion in the study if liver imaging (computed tomography [CT], magnetic resonance imaging [MRI], positron emission tomography [PET]-CT, or PET scan) performed within  days prior to randomization does not demonstrate metastatic disease and the requirements above are met
Patient must have clinically T-, N breast cancer at the time of diagnosis (before neoadjuvant therapy); clinical axillary nodal involvement can be assessed by palpation, ultrasound, CT scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan, or PET/CT scan
The patient must have the following assessments done =<  weeks prior to randomization:\r\n* Examination by a head and neck surgeon\r\n* Chest x-ray (or chest computed tomography [CT] scan or CT/positron emission tomography [PET] of the chest or magnetic resonance imaging [MRI]) to rule out distant metastatic disease
Patients with screening ALT/AST or ALP above institutional upper limit of normal should have liver ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI) at any time point between diagnosis of current breast cancer and randomization; screening bone scan is required if ALP and/or corrected calcium level are above the institutional upper limit; (note positron emission tomography [PET]/CT scan may be used as an alternative imaging technique)
Documentation by positron emission tomography(PET)/computed tomography (CT) scan, CT scan, or magnetic resonance imaging (MRI) that the patient has untreated measurable metastatic disease per RECIST .
? bone lesion identifiable by radiograph, computed tomography (CT), positron emission tomography - computed tomography (PET-CT), or magnetic resonance imaging (MRI).
Detectable disease by at least one of the following modalities: computed tomography (CT), positron emission tomography (PET), bone scan, or magnetic resonance imaging (MRI)
Subjects must be free of visible disease on imaging (computed tomography [CT], positron emission tomography CT [PETCT] or magnetic resonance imaging [MRI]) evaluating chest, abdomen, and pelvis within  days of enrollment on the study
Absence of lytic bone lesion on X-ray, computed tomography (CT), or positron emission tomography (PET)/CT and not more than  lesion on spinal magnetic resonance imaging (MRI) (NOTE: at the discretion of the investigator, PET/CT may replace MRI in patients who have a contraindication to MRI)
Stage M\r\n* Metastatic disease can be documented by bone scan or computed tomography (CT) scan or magnetic resonance imaging (MRI) or positron emission tomography (PET)/CT or the combination of these tests
Patients must have evaluable (microscopic marrow metastasis, elevated tumor markers, positive metaiodobenzylguanidine [MIBG] or positron emission tomography [PET] scans) or measurable (computed tomography [CT], magnetic resonance imaging [MRI]) disease documented after completion of prior systemic therapy
Has had restaging imaging after initiation of immunotherapy, at least  weeks after pre-immunotherapy baseline imaging; computed tomography (CT) or positron emission tomography (PET)/CT of at least chest/upper abdomen must be performed within  weeks prior to registration; for patients with history of brain metastases, brain magnetic resonance imaging (MRI) or CT is required within  weeks of registration; for other patients brain MRI or CT is required within  weeks of registration; diagnostic PET/CT performed as part of radiation simulation can be used as the restaging imaging
Staging by positron emission tomography (PET)-computed tomography (CT) scan (required) and magnetic resonance imaging (MRI) brain (if clinically indicated) showing no evidence of metastatic disease (mediastinoscopy is not required unless imaging is indeterminate and is then considered standard of care)
Neck computed tomography (CT) and/or neck magnetic resonance imaging (MRI), and whole body positron emission tomography (PET)-CT
Patients must have measurable disease, defined as at least one lesion that is >  mm (. cm) in the longest axis on cross-sectional imaging and measureable in two perpendicular dimensions per computed tomography (spiral computed tomography [CT]), positron emission tomography (PET)-CT or magnetic resonance imaging (MRI)
Patients with Stage IV breast cancer are not eligible; baseline staging to document absence of metastatic disease is not required, however is recommended as determined by institutional practice (in patients where there may be a reasonable suspicion of advanced disease e.g., large tumors, clinically positive axillary lymph nodes, signs and symptoms); if performed, reports of these examinations must be available; examination type for staging, i.e. X-ray, sonography, bone scans, computed tomography (CT), magnetic resonance imaging (MRI), and/or positron emission tomography (PET)-CT, is at the discretion of the investigator
Presence of radiographically measurable disease (defined as the presence of a >= . cm lesion, as measured in the longest dimension by computed tomography [CT] scan or positron emission tomography [PET]/CT scan or magnetic resonance imaging [MRI] scan)
Radiographic evidence of disease other than liver and lungs, with the exception of mediastinal lymph nodes <  cm and hepatoduodenal ligament lymphadenopathy, diagnosed by computed tomography, magnetic resonance imaging, or positron emission tomography
Disease status requirement: Measurable disease defined as the presence of ?  nodal lesion that measures ? . cm in a single dimension as assessed by X-ray Computed Tomography (CT) (Positron Emission Tomography (PET/CT), or magnetic resonance imaging [MRI]
Have baseline imaging within  weeks of enrollment (computed tomography [CT], magnetic resonance [MR] or positron emission tomography [PET]/CT imaging) and have measurable disease on physical examination or imaging studies; any lesion >= . cm in long axis dimension is considered measurable
Patients must have evaluable (microscopic marrow metastasis, elevated tumor markers, positive metaiodobenzylguanidine [MIBG] or positron emission tomography [PET] scans) or measurable (computed tomography [CT], magnetic resonance imaging MRI]) disease documented after completion of prior systemic therapy
Patients must have at least one bi-dimensionally measurable lesion by palpation, clinical exam, or radiographic imaging within  weeks of the start of study intervention (X-ray, computed tomography [CT] scan, positron emission tomography [PET] scan, magnetic resonance imaging [MRI], or ultrasound)
Patients must receive a magnetic resonance imaging (MRI)/computed tomography (CT)/positron emission tomography (PET) of the brain within  months of signing informed consent; if new central nervous system (CNS) lesions are present, patient must have definitive treatment (including surgery or radiation); principal investigator (PI) or his designee should make final determination regarding enrollment
The subject has documented worsening of disease (progressive disease) at screening compared with a previous computed tomography (CT) scan or magnetic resonance imaging (MRI) image done within  months of screening documentation of progression may be made by radiological (CT, MRI, or positron emission tomography [PET]), clinical or serological  assessment; if documentation is radiological, screening scan be compared to any previous scan (CT, MRI or PET) within  months of cycle  day  (CD)
Patients must receive a magnetic resonance imaging (MRI)/computed tomography (CT)/positron emission tomography (PET) of the brain within  months of signing informed consent; if new lesions are present, patient must have definitive treatment; principal investigator (PI) or his designee should make final determination regarding enrollment (Turnstile I)
Clinical T-stage (prior to systemic therapy, if applicable) >= Ta and/or positive lymph nodes by transurethral resection of bladder tumor (TURBT)/magnetic resonance imaging (MRI)/computed tomography (CT)/positron emission tomography (PET)-CT or
Patients must receive a magnetic resonance imaging (MRI)/computed tomography (CT)/positron emission tomography (PET) of the brain within  months of signing informed consent; if new lesions are present, patient must have definitive treatment; principal investigator (PI) or his designee should make final determination regarding enrollment (Turnstile I)
Clinical stage II and III NSCLC based on American Joint Committee on Cancer (AJCC) Cancer Staging Manual, seventh edition; acceptable imaging modalities to document nodal positivity include computed tomography (CT) chest, positron emission tomography (PET)-CT, or thoracic magnetic resonance imaging (MRI)
No evidence of distant metastatic disease as documented by magnetic resonance imaging (MRI) of the brain and positron emission tomography (PET)/computed tomography (CT)
Patients must receive an magnetic resonance imaging (MRI)/computed tomography (CT) of the brain or positron emission tomography (PET)/CT within  months of consenting; if new lesions are present, principal investigator (PI) or his designee should make final determination regarding enrollment (Turnstile I)
Patients with solid tumors must have measurable or evaluable (for neuroblastoma and Ewing sarcoma) disease. Tumor assessment will be done via computed tomography (CT), magnetic resonance imaging (MRI) or positron emission tomography-computed tomography (PET-CT). Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, may be considered measurable if there has been demonstrated progression in the lesion. Bone scans (if clinically indicated) should be obtained within ?  weeks prior to the start of treatment.
At least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline by computed tomography (CT), positron-emission tomography (PET), magnetic resonance imaging (MRI) and/or bone scan and is suitable for repeated assessment
The patient must be free of unresectable metastatic disease within  weeks prior to the surgery being performed with the intention to remove all melanoma; this pre-surgery baseline assessment must be documented by complete physical examination and imaging studies; imaging studies must include a total body positron emission tomography (PET)-computed tomography (CT) in conjunction with a brain magnetic resonance imaging (MRI) (or head CT if brain MRI is contraindicated); if a PET/CT scan cannot be done, a CT of the neck, chest, abdomen, and pelvis should be performed
Must have American Joint Committee on Cancer (AJCC) th edition (ed) inoperable stage II disease requiring chemoradiation therapy or stage IIIA or IIIB NSCLC based on appropriate staging studies including brain magnetic resonance imaging (MRI) or head computed tomography (CT), CT chest, and fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT scan
All patients must have disease-free status documented by a complete physical examination and imaging studies within  weeks prior to randomization; imaging studies must include a total body positron emission tomography (PET)-computed tomography (CT) scan (with or without brain) and brain magnetic resonance imaging (MRI) or CT (if MRI is contraindicated); if PET-CT cannot be done, CT of neck, chest, abdomen, and pelvis should be done\r\n* If for some reason a CT cannot be done, an MRI may be done instead; any other imaging studies if performed (eg, bone scan) must show no evidence of disease
A complete response to front-line chemotherapy must include: negative physical exam, negative pelvic exam and normalization of CA, if elevated at baseline; although not required, any radiographic assessment of disease status (e.g. CT, magnetic resonance imaging [MRI], positron emission tomography [PET]/CT, etc) obtained following the completion of primary therapy should be considered negative for disease
Bi-dimensionally measurable disease, with at least one mass lesion >=  cm in longest diameter\r\nby computed tomography (CT), positron emission tomography (PET)/CT, and/or magnetic resonance imaging (MRI)
Patients must have a magnetic resonance imaging (MRI), computed tomography (CT), or positron emission tomography (PET) of the brain within  months before consenting if known history of brain metastasis or if clinically indicated; if new lesions are present, principal investigator (PI) or designee should make final determination regarding enrollment
Subjects must have measurable or evaluable disease based on physical exam and/or radiographs (computed tomography [CT], magnetic resonance imaging [MRI], positron emission tomography [PET]) or bone marrow involvement
Patients must have evaluable (microscopic marrow metastasis, elevated tumor markers, positive metaiodobenzylguanidine [MIBG] or positron emission tomography [PET] scans) or measurable (computed tomography [CT], magnetic resonance imaging [MRI]) disease documented after completion of prior systemic therapy
Bi-dimensionally measurable disease, with at least one mass lesion >=  cm in longest diameter by computed tomography (CT), positron emission tomography (PET)/CT, and/or magnetic resonance imaging (MRI)
ELIGIBILITY FOR TREATMENT ON ARM : Bi-dimensionally measurable disease by palpation, clinical exam, or radiographic imaging (X-ray, computed tomography [CT] scan, positron emission tomography [PET] scan, magnetic resonance imaging [MRI], or ultrasound)
Histologic proof of stage II, III or IV melanoma that has been completely resected or completely treated with ablative therapy (ex: stereotactic body radiosurgery, radiofrequency ablation, cryoablation) with no current evidence of disease, as demonstrated by imaging within  months ( days: stage IIIB, IIIC or stage IV; must be computed tomography [CT], magnetic resonance imaging [MRI], or positron emission tomography [PET]/CT) or  months ( days: stage II or IIIA; may be chest x-ray, CT, MRI, or PET/CT)
Distant metastatic disease limited to peritoneum and radiologically occult (not visualized on preoperative imaging to include [computerized tomography] CT scan, ultrasound, [magnetic resonance imaging] MRI, positron emission tomography [PET]/CT): \r\n* Positive peritoneal cytology\r\n* Carcinomatosis on diagnostic laparoscopy or laparotomy
Metastatic disease on bone scan and/or involvement of soft tissues (lymph nodes and/or viscera) by computed tomography (CT) scan, positron emission tomography (PET)/CT, or magnetic resonance imaging (MRI)
Patients must have been evaluated by standard-of-care full body imaging studies (computed tomography [CT], positron emission tomography [PET]-CT or magnetic resonance imaging [MRI]) as part of the initial clinical work-up at baseline (no more than  weeks prior to study enrollment) and after completion of induction HDI-ipilimumab (at - weeks after the first dose of ipilimumab/HDI and prior to the definitive lymphadenectomy procedure)
Measurable disease: lesions that can be accurately measured in at least two dimensions as >= . x . cm by computerized tomography (CT), PET/CT (positron emission tomography/CT), or magnetic resonance imaging (MRI)
For patients with solid malignancies and lymphoma, radiographically detectable (either fludeoxyglucose-positron emission tomography [PET], computed tomography [CT] scan/magnetic resonance imaging [MRI] or bone scan) or measurable disease will be required; measurable disease is defined as at least one measurable lesion >=  mm on CT scan ( mm for nodal lesions)
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) or the CT portion of the positron emission tomography (PET)/CT: must have at least one lesion that has a single diameter of >=  cm or tumor cells in the blood >=  x ^/L; skin lesions can be used if the area is >=  cm in at least one diameter and photographed with a ruler
>=  measurable disease site on computed tomography (CT) scan or positron emission tomography (PET) (> . cm in longest dimension); (in select cases, for example extremity lesions, a magnetic resonance imaging [MRI] may be substituted)
Histologically or cytologically confirmed pancreatic adenocarcinoma that has metastatic disease measurable by computed tomography (CT), magnetic resonance imaging (MRI), or (positron emission tomography (PET)
Measurable disease by computed tomography (CT), magnetic resonance imaging (MRI), and/or positron emission tomography (PET) with at least one target lesion measuring . cm or larger
Bi-dimensionally measurable disease by palpation, clinical exam, or radiographic imaging (x-ray, computed tomography [CT] scan, positron emission tomography [PET] scan, magnetic resonance imaging [MRI], or ultrasound)
Patient must have histologically proven primary or recurrent extremity melanoma, stage IIIB, IIIC, or stage IV (American Joint Committee on Cancer [AJCC] staging must be documented in patients medical record, as determined by computed tomography [CT] of the chest, abdomen and pelvis, and/or whole body positron emission tomography [PET] scan, and magnetic resonance imaging [MRI] of the brain within  weeks prior to administration of study drug)
Patients must have been evaluated by standard-of-care full body imaging studies (computerized tomography [CT], positron emission tomography [PET]-CT or magnetic resonance imaging [MRI]) as part of the initial clinical work-up at baseline (no more than  weeks prior to study enrollment) and after completion of induction nivolumab-ipilimumab or nivolumab alone (at - weeks after the first dose of induction and prior to the definitive surgery procedure)
Systemic staging including computed tomography (CT) that covers the chest, liver and adrenal glands or a positron emission tomography (PET)/CT; magnetic resonance imaging (MRI) of the brain is required and must be negative for metastatic spread; if a patient is unable to tolerate MRI or has a contraindication to MRI, a head CT scan with and without contrast is acceptable
Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with computed tomography (CT) scan, positron emission tomography (PET) CT, or magnetic resonance imaging (MRI) exam
Patients must have no evidence of metastasis on positron emission tomography (PET) scan or magnetic resonance imaging (MRI) or computed tomography (CT) scan of the pelvis and chest imaging
No evidence of any lymph node spread or distant metastases as determined by positron emission tomography (PET) computed tomography (CT) imaging within  weeks of enrollment; alternatively, for those without PET CT capability, a magnetic resonance imaging (MRI) or CT of the abdomen and pelvis and a chest x-ray confirming no evidence of metastatic disease is acceptable
Subjects must have had a baseline scan (computed tomography [CT], magnetic resonance imaging [MRI], or positron emission tomography-computer tomography [PET/CT]) of the chest to assess disease burden before starting on first line chemotherapy for NSCLC and those images must have been reviewed by the investigator prior to randomization. If the scan was performed more than  days prior to randomization, an additional scan must be performed and reviewed by the investigator to confirm that the patient has not progressed before randomization.
Have a measurable lesion in the pelvis or abdomen, at a minimum of . cm in diameter on standard of care pre-operative imaging studies (computed tomography [CT], magnetic resonance imaging [MRI] or positron emission tomography [PET] scan)
Diagnosis of extensive stage disease (extensive stage [ES]-SCLC), with stage established by computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) scan